

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on December 21, 2006.



Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

Examining Group 1635

Patent Application

Docket No. USF-T150CX

Serial No. 09/955,174

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jane J. Zara, Ph.D.  
Art Unit : 1635  
Applicant : William G. Kerr  
Serial No. : 09/955,174  
Filed : September 19, 2001  
For : Control of NK Cell Function and Survival by Modulation of SHIP Activity

MS RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Glenn P. Ladwig  
Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/955,174	
			Filing Date	September 19, 2001	
			First Named Inventor	William G. Kerr	
			Group Art Unit	1635	
			Examiner Name	Jane J. Zara, Ph.D.	
Sheet	1	of	1	Attorney Docket Number	USF-T150CX

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	HANNON, G.J. and ROSSI, J.J. "Unlocking the potential of the human genome with RNA interference" <i>Nature</i> , 2004, 431:371-378.	
	R2	HEMANN, M.T. <i>et al.</i> "An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes <i>in vivo</i> " <i>Nature Genetics</i> , 2003, 33:396-400.	
	R3	OPALINSKA, J.B. and GEWIRTZ, A.M. "Nucleic-acid therapeutics: Basic principles and recent applications" <i>Nature Reviews</i> , 2002, 1:503-514.	
	R4	PERA, M.F. <i>et al.</i> "Human embryonic stem cells" <i>J. Cell Sci.</i> , 2000, 113:5-10.	
	R5	PUENTE, X.S. <i>et al.</i> "Human and mouse proteases: A comparative genomic approach" <i>Nature Reviews</i> , 2003, 4:544-558.	
	R6	RAUH, M.J. <i>et al.</i> "The role of SHIP1 in macrophage programming and activation" <i>Biochem. Soc. Trans.</i> , 2004, 32:785-788.	
	R7	REHLI, M. <i>et al.</i> "The membrane-bound ectopeptidase CPM as a marker of macrophage maturation <i>in vitro</i> and <i>in vivo</i> " <i>Adv. Exp. Med. Biol.</i> , 2000, 477:205-216.	
	R8	ROHRSCHEIDER, L.R. <i>et al.</i> "Structure, function, and biology of SHIP proteins" <i>Genes &amp; Develop.</i> , 2000, 14:505-520.	
	R9	VERFAILLIE, C.M. "Hematopoietic stem cells for transplantation" <i>Nature Immunology</i> , 2002, 3:314-317.	
	R10	ZANDSTRA, P.W. <i>et al.</i> "Leukemia inhibitory factor (LIF) concentration modulates embryonic stem cell self-renewal and differentiation independently of proliferation" <i>Biotechnol. Bioeng.</i> , 2000, 69:607-617.	
	R11	Examination Report dated November 11, 2006, issued in related European application number 01973144.7.	
	R12	GHANSAH, T. <i>et al.</i> "Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses" <i>J. Immunology</i> , 2004, 173:7324-7330.	
	R		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.